← Eichor
Study identifier: NCT06767527 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer

Condition: Triple-Negative Breast Cancer (TNBC)  ·  Sponsor: Akeso

PhasePhase 3
Planned participants416
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

This multicenter, randomized, double-blind study aims to assess the safety and efficacy of AK112 in combination with Nab-Paclitaxel, compared to a placebo plus Nab-Paclitaxel, as a first-line treatment for inoperable locally advanced or metastatic triple-negative breast cancer (TNBC).

This description comes directly from the study's public registry record.

Talk to the study team

Xufang Yu  ·  +86(0760)89873999  ·  clinicaltrials@akesobio.com

Always discuss trial participation with your own doctor first.

Locations (1)

Cancer Hospital Chinese Academy of Medical SciencesBeijing, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06767527